Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

Introduction: Geographic transferability of model-based cost effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost effectiveness study of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer from the United Kingdom to The Netherlands. Methods: Three successive steps were taken. Step I: Collect available information with regard to the original model, and assess transferability using existing checklists. Step 2: Adapt transferability-limiting factors. Step 3: Obtain... Mehr ...

Verfasser: Essers, Brigitte A. B.
Seferina, Shanley C.
Tjan-Heijnen, Vivianne C. G.
Severens, Johan L.
Novak, Annoesjka
Pompen, Marjolein
Oron, Ulrich H.
Joore, Manuela A.
Dokumenttyp: Artikel
Erscheinungsdatum: 2010
Reihe/Periodikum: Essers , B A B , Seferina , S C , Tjan-Heijnen , V C G , Severens , J L , Novak , A , Pompen , M , Oron , U H & Joore , M A 2010 , ' Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands ' , Value in Health , vol. 13 , no. 4 , pp. 375-380 . https://doi.org/10.1111/j.1524-4733.2009.00683.x
Schlagwörter: HER2-positive breast cancer / model-based economic evaluation / transferability / trastuzumab
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26822193
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://cris.maastrichtuniversity.nl/en/publications/e30a92cb-04bc-405d-b83f-7d34f4859174